Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 1, January, p. 77–82

doi: 10.17219/acem/67819

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Oxidative stress in colonic adenocarcinoma: An impact on the body’s antioxidative status and oxidative protein damage

Łukasz Murlikiewicz1,A,B,C,D, Krzysztof Grzegorczyk2,B, Małgorzata Lewicka3,E,F, Andrzej Buczyński3,E,F, Maciej Rutkowski4,A,C,D

1 Department of General and Oncological Surgery, Regional Integrated Hospital, Płock, Poland

2 Department of Endoscopy and One Day Gastroenterology, Regional Specialist Hospital of dr Wł. Biegański in Łódź, Poland

3 Department of Epidemiology and Public Health, Medical University of Lodz, Poland

4 Department of Military Toxicology and Radiological Protection, Medical University of Lodz, Poland

Abstract

Background. Thus far, the pathogenesis of these intestinal tumors has not been fully explained. However, the analysis of risk factors and research regarding their formation that have continued for 3 decades have allowed us to demonstrate a significant role of oxidative stress in the processes leading to the development of cancer in the large intestine as well as in some other organs.
Objectives. The aim of the study was to examine the level of anti-oxidative status and the degree of oxidative protein damage in patients with varying severity of colonic adenocarcinoma (CAC) in relation to healthy individuals.
Material and Methods. The study involved 4 groups (A–D) of patients with increasing severity of CAC stages according to Dukes’ classification and a control group of healthy volunteers. Total antioxidant capacity (TAC) of blood plasma, as well as carbonyl (C=O) group contents in blood plasma proteins as a product of their oxidative damage, were estimated in all participants. Both parameters were determined by spectrophotometric methods using commercial kit to test TAC and 2,4-dinitrophenylhydrazine to assay the contents of C=O groups.
Results. In each of the studied groups, A–D, a statistically significant reduction in the TAC values was noted relative to the control group, which progressed with increased severity of CAC stages: 1.783 mmol/L vs 1.191 mmol/L (group A), 1.07 mmol/L (group B), 0.931 mmol/L (group C), and 0.899 mmol/L (group D). At the same time, significantly increased contents of protein C=O groups were observed compared to the controls, also progressive in the course of growing CAC severity: 0.496 nmol/mg protein vs 0.57 nmol/mg protein (group A), 0.689 nmol/mg protein (group B), 0.804 nmol/mg protein (group C), and 1.054 nmol/mg protein (group D).
Conclusion. The CAC-related oxidative stress considerably reduces the systemic anti-oxidative status and increases the protein damage; both those changes become worse in parallel with the progression of this cancer.

Key words

oxidative stress, total antioxidant capacity, colonic adenocarcinoma, oxidative protein damage

References (31)

  1. Wojciechowska U, Didkowska J, Zatoński W. Nowotwory złośliwe w Polsce w 2008 roku. [Cancer in Poland in 2008.] Warszawa: Centrum Onkologii, Instytut im. M. Skłodowskiej-Curie; 2010:20–21.
  2. Regula J, Rupinski M, Kraszewska E, et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med. 2006;355:1863–1872.
  3. López-Alarcóna C, Denicola A. Evaluating the antioxidant capacity of natural products: A review on chemical and cellular-based assays. Anal Chim Acta. 2013;763:1–10.
  4. Afanas’ev I. Reactive oxygen species signaling in cancer: Comparison with aging. Aging Dis. 2011;2:219–230.
  5. Liu J, Zhang X, Yang F, Li T, Wei D, Ren Y. Antimetastatic effect of a lipophilic ascorbic acid derivative with antioxidation through inhibition of tumor invasion. Cancer Chemother Pharmacol. 2006;57:584–590.
  6. Błauż A, Pilaszek T, Grzelak A, Dragan A, Bartosz G. Interaction between antioxidants in assays of total antioxidant capacity. Food Chem Toxicol. 2008;46:2365–2368.
  7. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci. 1993;84:407–412.
  8. Levine RL, Garland D, Oliver CN. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990;186:464–478.
  9. Brodzki A, Brodzki P, Tatara MR, Kostro K. Total antioxidative capacity and zinc concentration in dogs suffering from perianal tumours. Bull Vet Inst Pulawy. 2015;59: 417–423.
  10. Gupta A, Bhatt ML, Misra MK. Lipid peroxidation and antioxidant status in head and neck squamous cell carcinoma patients. Oxid Med Cell Longev. 2009;2:68–72.
  11. Subramanyam D, Subbaiah KV, Rajendra W, Lokanatha V. Serum selenium concentration and antioxidant activity in cervical cancer patients before and after treatment. Exp Oncol. 2013;35(2):97–100.
  12. Erhola M, Nieminen MM, Kellokumpu-Lehtinen P. Effects of surgical removal of lung cancer on total plasma antioxidant capacity in lung cancer patients. J Exp Clin Cancer Res. 1998;17:219–225.
  13. Hietanen E, Bartsch H, Béréziat JC. Diet and oxidative stress in breast, colon and prostate cancer patients: A case-control study. Eur J Clin Nutr. 1994;48:575–586.
  14. Czeczot H, Skrzycki M, Podsiad M, Gawryszewska E, Nyckowski P, Porembska Z. Antioxidant status of patients with primary colorectal cancer and liver metastases of colorectal cancer. Pol Merk Lek. 2005;18:58–61.
  15. Saygili EI, Akcay T, Konukoglu D, Papila C. Glutathione and glutathione-related enzymes in colorectal cancer patients. J Toxicol Environ Health A. 2003;14:411–415.
  16. Kocot J, Kiełczykowska M, Dąbrowski W, Piłat J, Rudzki S, Musik I. Total antioxidant status value and superoxide dismutase activity in human colorectal cancer tissue depending on stage of the disease: A pilot study. Adv Clin Exp Med. 2013;22(3):431–443.
  17. Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev. 2014;2014:360438.
  18. Valavanidis A, Vlachogianni T, Fiotakis C. 8-Hydroxy-2-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009;27:120–139.
  19. Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxidation in aging and disease. Drug Metab Rev. 1998;30:225–243.
  20. Ponczek MB, Wachowicz B. Interaction of reactive oxygen and nitrogen species with proteins. Postepy Biochem. 2005;51:140–145.
  21. Renke J, Popadiuk S, Korzon M, Bugajczyk B, Woźniak M. Protein carbonyl groups’ content as a useful clinical marker of antioxidant barrier impairment in plasma of children with juvenile chronic arthritis. Free Radic Biol Med. 2000;29:101–104.
  22. Yilmaz IA, Akçay T, Cakatay U, Telci A, Ataus S, Yalcin V. Relation between bladder cancer and protein oxidation. Int Urol Nephrol. 2003;35:345–350.
  23. Chang D, Wang F, Zhao YS, Pan HZ. Evaluation of oxidative stress in colorectal cancer patients. Biomed Environ Sci. 2008;21:286–289.
  24. Avinash SS, Anitha M, Vinodchandran, Rao GM, Sudha K, Shetty BV. Advanced oxidation protein products and total antioxidant activity in colorectal carcinoma. Indian J Physiol Pharmacol. 2009;53:370–374.
  25. Hamada J, Nakata D, Nakae D. Increased oxidative DNA damage in mammary tumor cells by continuous epidermal growth factor stimulation. J Natl Cancer Inst. 2001;93:214–219.
  26. Lusini L, Tripodi SA, Rossi R. Altered glutathione anti-oxidant metabolism during tumor progression in human renal-cell carcinoma. Int J Cancer. 2001;91:55–59.
  27. Dawane JS, Pandit VA. Understanding redox homeostasis and its role in cancer. J Clin Diagn Res. 2012;6(10):1796–1802.
  28. Mantovani G, Macciò A, Madeddu C. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: Correlation with stage and performance status. Int J Cancer. 2002;98:84–91.
  29. Mantovani G, Macciò A, Madeddu C. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: Assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med. 2003;81:664–673.
  30. Leung EY, Crozier JE, Talwar D. Vitamin antioxidants, lipid peroxidation, tumour stage, the systemic inflammatory response and survival in patients with colorectal cancer. Int J Cancer. 2008;123:2460–2464.
  31. Guan F, Li G, Liu AB. δ- and γ-tocopherols, but not α-tocopherol, inhibit colon carcinogenesis in azoxymethane-treated F344 rats. Cancer Prev Res. 2012;5:644–654.
© Wroclaw Medical University